Novel and revisited approaches in antituberculosis drug discovery.

[1]  S. Gowrishankar,et al.  Antimycobacterial, Enzyme Inhibition, and Molecular Interaction Studies of Psoromic Acid in Mycobacterium tuberculosis: Efficacy and Safety Investigations , 2018, Journal of clinical medicine.

[2]  K. Tahlan,et al.  Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance , 2018, The Journal of Membrane Biology.

[3]  V. Mizrahi,et al.  Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis , 2017, Front. Mol. Biosci..

[4]  K. Altmann,et al.  Recent developments in natural product-based drug discovery for tuberculosis. , 2017, Drug discovery today.

[5]  R. Payne,et al.  New tuberculosis drug leads from naturally occurring compounds. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[6]  B. Meibohm,et al.  Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. , 2017, ACS infectious diseases.

[7]  A. Diacon,et al.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial , 2017, The Lancet. Infectious diseases.

[8]  G. Besra,et al.  Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen , 2016, Scientific Reports.

[9]  S. Cole.  Inhibiting Mycobacterium tuberculosis within and without , 2016, Philosophical Transactions of the Royal Society B: Biological Sciences.

[10]  K. Floyd,et al.  Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. , 2016, The New England journal of medicine.

[11]  Richard E. Lee,et al.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis. , 2016, Advanced drug delivery reviews.

[12]  D. Newman,et al.  Natural Products as Sources of New Drugs from 1981 to 2014. , 2016, Journal of natural products.

[13]  Eric F van Herwerden,et al.  Sources for Leads: Natural Products and Libraries. , 2016, Handbook of experimental pharmacology.

[14]  H. Petković,et al.  Strategies for the Discovery and Development of New Antibiotics from Natural Products: Three Case Studies. , 2016, Current topics in microbiology and immunology.

[15]  G. Bloemberg,et al.  Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. , 2015, The New England journal of medicine.

[16]  B. Meibohm,et al.  In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics , 2015, Scientific Reports.

[17]  A. Nyarko,et al.  Current perspectives in drug discovery against tuberculosis from natural products. , 2015, International journal of mycobacteriology.

[18]  S. Cole,et al.  Lansoprazole is an antituberculous prodrug targeting cytochrome bc1 , 2015, Nature Communications.

[19]  Gonzalo Colmenarejo,et al.  Identification of Novel Anti-mycobacterial Compounds by Screening a Pharmaceutical Small-Molecule Library against Nonreplicating Mycobacterium tuberculosis. , 2015, ACS infectious diseases.

[20]  H. Matter,et al.  Targeting DnaN for tuberculosis therapy using novel griselimycins , 2015, Science.

[21]  A. Diacon,et al.  Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. , 2015, The Journal of antimicrobial chemotherapy.

[22]  Wonsik Lee,et al.  Novel Inhibitors of Cholesterol Degradation in Mycobacterium tuberculosis Reveal How the Bacterium’s Metabolism Is Constrained by the Intracellular Environment , 2015, PLoS pathogens.

[23]  H. J. Kim,et al.  Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent. , 2014, Journal of medicinal chemistry.

[24]  S. Cole,et al.  New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. , 2014, The Lancet. Infectious diseases.

[25]  D. Goel.  Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis , 2014, Journal of pharmacology & pharmacotherapeutics.

[26]  T. Buclin,et al.  Towards a new combination therapy for tuberculosis with next generation benzothiazinones , 2014, EMBO molecular medicine.

[27]  Karl-Heinz Altmann,et al.  Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. , 2014, Nature chemical biology.

[28]  B. Meibohm,et al.  Spectinamides: A New Class of Semisynthetic Anti-Tuberculosis Agents that Overcome Native Drug Efflux , 2014, Nature Medicine.

[29]  S. Cole,et al.  Tuberculosis drug discovery in the post-post-genomic era , 2014, EMBO molecular medicine.

[30]  V. Makarov,et al.  DprE1--from the discovery to the promising tuberculosis drug target. , 2013, Current pharmaceutical design.

[31]  Kunio Inoue,et al.  Inhibition of the First Step in Synthesis of the Mycobacterial Cell Wall Core, Catalyzed by the GlcNAc-1-phosphate Transferase WecA, by the Novel Caprazamycin Derivative CPZEN-45* , 2013, The Journal of Biological Chemistry.

[32]  Se Yeon Kim,et al.  Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis , 2013, Nature Medicine.

[33]  Alimuddin Zumla,et al.  Advances in the development of new tuberculosis drugs and treatment regimens , 2013, Nature Reviews Drug Discovery.

[34]  Kunio Inoue,et al.  Novel semisynthetic antibiotics from caprazamycins A–G: caprazene derivatives and their antibacterial activity , 2013, The Journal of Antibiotics.

[35]  S. Cole,et al.  Synthesis and antimycobacterial activity of 2,1'-dihydropyridomycins. , 2013, ACS medicinal chemistry letters.

[36]  S. Cole,et al.  Towards a new tuberculosis drug: pyridomycin – nature's isoniazid , 2012, EMBO molecular medicine.

[37]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[38]  G. Carter,et al.  Natural products and Pharma 2011: strategic changes spur new opportunities. , 2011, Natural product reports.

[39]  J. Cechetto,et al.  High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. , 2010, Future medicinal chemistry.

[40]  K. Kuhen,et al.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy , 2010, Nature Communications.

[41]  T. Bugg,et al.  Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure-function studies and nucleoside biosynthesis. , 2010, Natural product reports.

[42]  R. Goldman,et al.  Discovery and validation of new antitubercular compounds as potential drug leads and probes. , 2009, Tuberculosis.

[43]  J. Holton,et al.  A steric block in translation caused by the antibiotic spectinomycin. , 2007, ACS chemical biology.

[44]  S. Schwarz,et al.  Mutations in 16S rRNA and Ribosomal Protein S5 Associated with High-Level Spectinomycin Resistance in Pasteurella multocida , 2007, Antimicrobial Agents and Chemotherapy.

[45]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[46]  H. Naganawa,et al.  Caprazamycins, Novel Lipo-nucleoside Antibiotics, from Streptomyces sp. , 2005, The Journal of Antibiotics.

[47]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[48]  H. Naganawa,et al.  Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp. , 2003, The Journal of antibiotics.

[49]  V. Ramakrishnan,et al.  Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics , 2000, Nature.

[50]  B. Lei,et al.  Action Mechanism of Antitubercular Isoniazid , 2000, The Journal of Biological Chemistry.

[51]  P. Sensi.  History of the development of rifampin. , 1983, Reviews of infectious diseases.

[52]  E. Novak,et al.  The Tolerance of High Dose Intravenous Spectinomycin Therapy in Man , 1974, Journal of clinical pharmacology.

[53]  J. Knox,et al.  Treatment of Gonorrhea with Spectinomycin Hydrochloride: Comparison with Standard Penicillin Schedules , 1972, Antimicrobial Agents and Chemotherapy.

[54]  B. Terlain,et al.  [Structure of griselimycin, polypeptide antibiotic extracted from streptomyces cultures. II. Structure of griselimycin]. , 1971, Bulletin de la Societe chimique de France.

[55]  H. Noufflard-Guy-Loé,et al.  [Experimental antituberculous action of a new antibiotic: RP 11,072]. , 1965, Revue de tuberculose et de pneumologie.

[56]  H. Umezawa,et al.  A new antibiotic, pyridomycin. , 1953, The Journal of antibiotics.

[57]  R. P. Glover,et al.  Clinical use of streptomycin in the treatment of tuberculosis. , 1946, Diseases of the chest.